Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sotera Health Company (SHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sotera Health is a Nasdaq-listed provider of mission-critical sterilization solutions, lab testing and advisory services for the healthcare industry, operating through its Sterigenics, Nordion and Nelson Labs businesses.
Investors can review Form 8-K filings that report material events such as quarterly financial results, secondary offerings of common stock by selling stockholders, amendments to credit agreements and settlements of specific legal matters. For example, recent 8-Ks describe secondary offerings in which affiliates of Warburg Pincus LLC and GTCR LLC sold shares of SHC, with the company noting that it did not receive proceeds from those sales. Other 8-Ks outline amendments to a first lien credit agreement and the terms of repriced term loans maturing in 2031.
Filings also discuss legal and regulatory developments, including a binding term sheet to resolve a defined group of ethylene oxide claims related to a former Sterigenics facility, and broader risk factors associated with EO and Co-60, regulatory compliance, international operations and leverage. These disclosures help readers understand the legal, operational and financial context around Sotera Health’s sterilization and lab testing activities.
On Stock Titan, users can track new SHC filings as they appear on EDGAR and use AI-powered summaries to interpret complex documents. This includes understanding the implications of current reports on Form 8-K, as well as locating annual and quarterly reports when they are filed, to see segment information for Sterigenics, Nordion and Nelson Labs, capital structure details and updated risk factor discussions.
Sotera Health Company reported another year of growth in 2025 and issued its 2026 outlook. Full‑year 2025 net revenues rose 5.7% to $1.164 billion, with net income increasing to $78 million or $0.27 per diluted share. Adjusted EBITDA grew 8.2% to $594 million and Adjusted EPS reached $0.86.
Leverage improved as the Net Leverage Ratio fell to 3.2x with cash of $345 million and total debt of $2.2 billion. For 2026, the company targets net revenues of $1.233–$1.251 billion and Adjusted EBITDA of $632–$641 million. The filing also details a planned transition of General Counsel, with Alex Dimitrief retiring from the role and becoming an advisor while Erika Ostrowski is promoted to Senior Vice President and General Counsel effective April 1, 2026.
Sessa Capital and related entities have disclosed a significant ownership stake in Sotera Health Co. As of 12/31/2025, they report beneficial ownership of 20,550,000 shares of Sotera Health common stock, representing 7.23% of the outstanding class.
Sessa Capital (Master), L.P. holds 15,919,619 shares (5.60%), and Sessa Capital Special Opportunity Fund II, L.P. holds 4,630,381 shares (1.63%). All reporting persons, including John Petry, have shared voting and dispositive power over these shares and no sole voting or dispositive power.
The filing is on Schedule 13G, and the reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Sotera Health, other than in connection with certain nomination activities referenced in the certification.
Sculptor Capital entities report a 7.39% passive stake in Sotera Health Company common stock. They collectively beneficially own 21,000,000 shares of Sotera’s common stock, based on 284,093,929 shares outstanding referenced from the issuer’s 10-Q. The shares are held across various investment accounts managed by Sculptor Capital LP and Sculptor Capital II LP, with related holding and parent entities also listed as beneficial owners. The filers certify the securities are not held to change or influence control of Sotera Health, but as a passive investment under Schedule 13G.
Sotera Health Company director Kyle Richard G filed an initial ownership report stating that he currently holds no securities of Sotera Health. This Form 3 identifies his role as a director and confirms that, as of the reported event date, there are no shares or derivative securities beneficially owned.
Sotera Health Co director files insider report. Director Kyle Richard G submitted a Form 4 related to Sotera Health Co, indicating an earliest transaction date of 02/04/2026. The excerpted tables for non-derivative and derivative securities do not show specific transaction amounts or prices.
Sotera Health Company expanded its Board of Directors from eleven to twelve members and appointed Richard G. Kyle as a Class III director, effective February 4, 2026. He will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.
Kyle is the former President and Chief Executive Officer of The Timken Company and continues to serve on Timken’s board, as well as the board of Sonoco Products Company. He has been deemed an independent director under Nasdaq rules and will receive standard non-employee director cash and restricted stock unit compensation under Sotera Health’s existing policy.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 19,228,375 shares of Sotera Health Co common stock, representing 6.76% of the class as of 12/31/2025.
Vanguard reports no sole voting or dispositive power, with shared voting power over 1,574,791 shares and shared dispositive power over 19,228,375 shares. The filing explains that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries or business divisions that are deemed beneficial owners are expected to report holdings separately on a disaggregated basis while pursuing the same investment strategies as before.
The shares are held for Vanguard’s clients, including registered investment companies and other managed accounts, which have rights to dividends and sale proceeds. Vanguard certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Sotera Health.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in Sotera Health Co common stock. As of 12/31/2025, BlackRock reports beneficial ownership of 17,739,027 shares, representing 6.2% of Sotera Health’s outstanding common stock. BlackRock has sole power to vote 17,194,322 shares and sole power to dispose of 17,739,027 shares, with no shared voting or dispositive power.
The filing states that these securities are held by certain BlackRock business units and that various underlying persons have rights to dividends or sale proceeds, but no single underlying holder has more than five percent of Sotera Health’s outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Sotera Health.
Sotera Health Company furnished an update with preliminary revenue results for full-year 2025. The company issued a press release on January 12, 2026 summarizing approximate revenue based on information available as of that date. These preliminary figures are still subject to completion of year-end closing procedures and audit by the independent registered public accounting firm, and the company notes that the approximation falls within the guidance provided at the time of its third quarter earnings release.
The update also notes that management is delivering a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. A slide presentation and webcast link or replay can be accessed through the Investor Relations section of the company’s website. The information about preliminary results and the conference presentation is being furnished, not filed, and is not automatically incorporated into other securities law filings.
Sotera Health Company’s major shareholder group affiliated with Warburg Pincus reported a large insider sale of common stock. On December 3, 2025, certain Warburg Pincus entities sold 9,720,000 shares of Sotera Health common stock in a transaction executed under Rule 144 at a price of $16.33 per share.
After this sale, the reporting entities still beneficially own 34,102,952 shares of Sotera Health, held indirectly through Bull Holdco L.P. with 27,291,923 shares and Bull Co-Invest L.P. with 6,811,029 shares. The various Warburg Pincus funds and affiliates report their interest as directors-by-deputization for Section 16 purposes and each disclaims beneficial ownership beyond its economic interest.